FPIN's Help Desk Answers
Growth Hormone for Treatment of Idiopathic Short Stature in Children
Am Fam Physician. 2015 Jul 1;92(1):64.
Is recombinant growth hormone (rGH) effective in the treatment of idiopathic short stature in children?
Final adult height is modestly increased in children who receive rGH, with growth increases of 3.5 to 7.5 cm. However, the use of rGH does not improve health-related quality of life. (Strength of Recommendation: B, based on systematic reviews of low-quality randomized controlled trials [RCTs] and nonrandomized trials.)
A Cochrane review examined the effect of treatment with rGH vs. no treatment or placebo in 741 children with height less than the 3rd percentile who had no apparent underlying pathology.1 One trial found that the nearfinal height in 10 pubertal girls who received 30 IU of rGH per m2 per week for three years was 7.5 cm greater than that in 30 untreated girls (155 cm vs. 148 cm; P = .003). Another trial that reported adult height found that 37 children who received rGH were 3.7 cm taller than those in the placebo group (P < .04). The remaining eight trials reported short-term height gains, which varied from none to 0.7 standard deviations in a year. One study that reported health-related quality of life found no significant improvement in 20 children who received rGH compared with 20 children in a control group. The quality of the studies was rated as moderate for two, poor for six, and very poor for two.
A systematic review included only trials that evaluated adult height (three RCTs [N = 115] and seven nonrandomized trials [N = 477]).2 Participants had a growth velocity of less than 1.5 cm per year or a bone age of 15 years in females or 16 years in males. The treatment group in the RCTs received 0.033 to 0.067 mg of rGH per kg per day. The adult height of the treated group exceeded that of the control group, with a mean difference of 0.65 standard deviations (about 4 cm; 95% confidence interval [CI], 0.40 to 0.91). In the seven nonrandomized trials, the mean adult height of treated children exceeded that of the control group by a mean difference of 0.45 standard deviations (about 3 cm; 95% CI, 0.18 to 0.73). Eight of the studies were rated low quality because of a high percentage of dropouts, and two of the RCTs were rated moderate quality.
In 2008, 32 leaders in the field of idiopathic short stature published a consensus statement based on a review of the literature and clinical experience.3 The consensus was that rGH therapy following country-specific regulatory guidelines is appropriate, and that stronger consideration should be given to shorter children. The mean increase in adult height with rGH therapy is 3.5 to 7.5 cm.
Copyright Family Physicians Inquiries Network. Used with permission.
1. Bryant J, et al. Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database Syst Rev. 2007;(3):CD004440.
2. Deodati A, et al. Impact of growth hormone therapy on adult height of children with idiopathic short stature: systematic review. BMJ. 2011;342:c7157.
3. Cohen P, et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature. J Clin Endocrinol Metab. 2008;93(11):4210–4217.
Help Desk Answers provides answers to questions submitted by practicing family physicians to the Family Physicians Inquiries Network (FPIN). Members of the network select questions based on their relevance to family medicine. Answers are drawn from an approved set of evidence-based resources and undergo peer review.
The complete database of evidence-based questions and answers is copyrighted by FPIN. If interested in submitting questions or writing answers for this series, go to http://www.fpin.org or e-mail: firstname.lastname@example.org.
This series is coordinated by John E. Delzell, Jr., MD, MSPH, Assistant Medical Editor.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Oct 15, 2018
Access the latest issue of American Family Physician